Quick Answer
Nuvalent, Inc. reported Research And Development Expense of $306.97 million for the year ending 2025.
- Nuvalent, Inc. showed an increase of +41.0% in Research And Development Expense from 2024 to 2025.
- This data is from Nuvalent, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $3.66 million | Q3 2020: $3.72 million | Q1 2021: $5.48 million | Q2 2021: $7.83 million | Q3 2021: $9.06 million | Q1 2022: $12.69 million | Q2 2022: $13.56 million | Q3 2022: $14.63 million | Q1 2023: $22.13 million | Q2 2023: $25.92 million | Q3 2023: $29.61 million | Q1 2024: $38.63 million | Q2 2024: $49.17 million | Q3 2024: $60.55 million | Q1 2025: $74.42 million | Q2 2025: $80.91 million | Q3 2025: $83.84 million.
- Over the full 6 years of available data (2020 to 2025), Nuvalent, Inc.'s Research And Development Expense has grown by 1,892.9%.
- Historical annual values: Fiscal year 2025: $306.97 million | Fiscal year 2024: $217.77 million | Fiscal year 2023: $113.24 million | Fiscal year 2022: $63.73 million | Fiscal year 2021: $35.56 million | Fiscal year 2020: $15.40 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: